-

NATI Stock Alert: Shareholders With Large Losses in National Instruments Corporation Should Contact Robbins LLP About Their Rights and Remedies

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of all sellers of National Instruments Corporation (NASDAQ: NATI) common stock between May 25, 2022 and January 17, 2023. National Instruments is a producer of automated test equipment and virtual instrumentation software. Since October 2023, National Instruments operates as Emerson Electric Co.’s (NYSE: EMR) Test and Measurement business unit after being acquired by Emerson.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: National Instruments Corporation (NATI) Failed to Disclose a Formal Acquisition Offer from Emerson Electric Co. (EMR)

According to the complaint, during the class period, defendants failed to disclose material information that artificially deflated the price of National Instruments common stock. Plaintiff alleges that while National Instruments was repurchasing National Instruments stock, defendants knew that National Instruments had received a formal acquisition offer from Emerson to purchase all outstanding shares of National Instruments common stock at prices significantly above its then-current market price and significantly above the price at which National Instruments was repurchasing its common stock from unsuspecting class members. Accordingly, National Instruments had an obligation to disclose that it had received a formal acquisition offer from Emerson or abstain from purchasing National Instruments stock from unsuspecting investors.

What Now: Similarly situated shareholders may be eligible to participate in the class action against National Instruments Corporation. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP. Plaintiffs must file their lead plaintiff papers by January 29, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against National Instruments Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:NATI

Release Summary
National Instruments Corporation (NATI) Failed to Disclose a Formal Acquisition Offer from Emerson Electric Co. (EMR)
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Regencell Bioscience Holdings Limited Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

Investor Notice: Robbins LLP Informs Investors of the Globant S.A. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Globant S.A. (NYSE: GLOB) common stock between February 15, 2024 and August 14, 2025. Globant is a Luxembourg-incorporated international technology company that provides digital consulting and related services. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LL...

Investor Notice: Robbins LLP Informs Investors of the zSpace, Inc. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired zSpace, Inc. (NASDAQ: ZSPC) securities pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company's December 2024 initial public statement ("IPO"). zSpace purports to be a leading provider of augmented reality (AR) and virtual reality (VR) educational technology solutions.For more information, s...
Back to Newsroom